Norges Bank Takes $4.02 Million Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Norges Bank purchased a new position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 417,900 shares of the company's stock, valued at approximately $4,020,000. Norges Bank owned approximately 0.28% of MiMedx Group at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. IMG Wealth Management Inc. bought a new stake in MiMedx Group during the fourth quarter worth about $28,000. SkyView Investment Advisors LLC lifted its holdings in shares of MiMedx Group by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock valued at $77,000 after purchasing an additional 3,000 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of MiMedx Group by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock worth $328,000 after purchasing an additional 3,292 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of MiMedx Group by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock worth $4,849,000 after buying an additional 3,300 shares during the last quarter. Finally, Van ECK Associates Corp purchased a new position in MiMedx Group during the fourth quarter valued at $40,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Stock Down 1.2 %

MDXG traded down $0.08 during trading on Tuesday, hitting $6.69. 202,633 shares of the company's stock traded hands, compared to its average volume of 694,307. The stock has a market capitalization of $985.88 million, a price-to-earnings ratio of 12.16 and a beta of 1.74. The company's 50 day simple moving average is $7.82 and its two-hundred day simple moving average is $8.01. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

Remove Ads

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million for the quarter, compared to analysts' expectations of $89.42 million. Analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com raised shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 4th.

Insider Transactions at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the transaction, the chief accounting officer now owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock worth $1,130,312 over the last three months. 1.30% of the stock is currently owned by company insiders.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.